Spatial Proteomics

Unlocking New Insights in Tissue Microenvironments

Our Capabilities

Lorem ipsum dolor sit amet consectetur adipisicing elit sed

Technology Highlights

Lorem ipsum dolor sit amet consectetur adipisicing elit sed

Overview

Unlocking New Insights in Tissue Microenvironments

Understanding the intricate behavior of individual cells is critical in today’s biomedical research, especially for immune system analysis, disease progression, and therapeutic response.

Imaging Mass Cytometry™ (IMC™)

The dynamics of tissue microenvironments play a crucial role in understanding disease progression, therapeutic response, and biomarker discovery. Imaging Mass Cytometry™ (IMC™) technology, powered by the Hyperion™ XTi Imaging System, enables researchers to explore the complexity of these dynamics with unparalleled precision. By detecting over 40 protein and RNA markers simultaneously in tissue samples, IMC uncovers spatial relationships that conventional imaging methods overlook.

 

Discover the throughput and precision that is uniquely designed for translational researchers.

Capabilities

Unparalleled Multiplexing Capability

Understanding the intricate behavior of individual cells is critical in today’s biomedical research, especially for immune system analysis, disease progression, and therapeutic response.

High Dynamic Range

Unlike traditional fluorescence-based imaging techniques, which often struggle with signal saturation and autofluorescence, IMC captures both high and low levels of protein expression in the same sample with exceptional clarity.

Assay development time

Because IMC technology uses an antibody reagent cocktail, it is simple to mix and match different antibodies without extensive assay validation.

Simultaneous Detection of 40+ Markers

Identify therapeutic targets that may be relevant to developing treatment strat…

Flexibility of tissue acquisition

With the Hyperion XTi™ Slide Loader, researchers can image up to 40 slides in 24 hours, making it easier to process large-scale studies and accelerate results without compromising precision – run an entire study in an automated, walkaway run.

No Autofluorescence Interference

IMC utilizes metal-tagged antibodies instead of fluorophores, eliminating issues with autofluorescence and delivering cleaner, more reliable data, even from challenging tissue samples.

Fluorescence-Based Imaging

Traditional

Traditional imaging methods, such as cyclic immunofluorescence, are limited by their low dynamic range, autofluorescence interference, and slow, multi-cycle processes. For example, brightfield imaging (DAB) gives at best one order of magnitude (OoM) of dynamic range, while fluorescence gives 2–3 OoM and IMC gives 5 OoM.

Our Solution

Fluorescence-Based Imaging

Standard Biotools

IMC overcomes these challenges by capturing the full dynamic range of spatial biomarkers, detecting both high- and low-expressing proteins simultaneously. This approach eliminates the need for multiple imaging cycles and delivers high-resolution, quantitative data without the drawbacks of autofluorescence. IMC provides up to 100 times higher throughput than cyclic fluorescence, making it the ideal solution for large-scale research studies.

Staining Redundancy

< 20 Markers

Spectral Overlap

Fluorescence-Based Imaging

Traditional

Traditional imaging methods, such as cyclic immunofluorescence, are limited by their low dynamic range, autofluorescence interference, and slow, multi-cycle processes. For example, brightfield imaging (DAB) gives at best one order of magnitude (OoM) of dynamic range, while fluorescence gives 2–3 OoM and IMC gives 5 OoM.

Our Solution

Fluorescence-Based Imaging

Standard Biotools

IMC overcomes these challenges by capturing the full dynamic range of spatial biomarkers, detecting both high- and low-expressing proteins simultaneously. This approach eliminates the need for multiple imaging cycles and delivers high-resolution, quantitative data without the drawbacks of autofluorescence. IMC provides up to 100 times higher throughput than cyclic fluorescence, making it the ideal solution for large-scale research studies.

Staining Redundancy

< 20 Markers

Spectral Overlap

Technology

Imaging Mass Cytometry Technology

Imaging Mass Cytometry™ (IMC™) is the most trusted technology that enables researchers to accurately assess complex phenotypes and immune spatial interactions in the tissue microenvironment.

Hyperion XTi

CyTOF XT detects over 50 markers at once, far exceeding the limits of traditional flow cytometry. This enables a comprehensive analysis of immune populations and functional responses in a single experiment.

42%

with no autofluorescence interference

42%

with no autofluorescence interference

Discover the power of Imaging Mass Cytometry

Image any tissue type

with no autofluorescence interference

Image any tissue type

with no autofluorescence interference

Image any tissue type

with no autofluorescence interference

Image any tissue type

with no autofluorescence interference

Image any tissue type

with no autofluorescence interference

Image any tissue type

with no autofluorescence interference

Applications

Lorem ipsum dolor sit amet consectetur

Dual Mode

Use your Hyperion XTi Imaging System to perform high-multiplex analysis of b…

Immuno-Oncology

Discover the impact of new immune therapies including checkpoint inhibit…

Dual Mode

Use your Hyperion XTi Imaging System to perform high-multiplex analysis of b…

Immuno-Oncology

Discover the impact of new immune therapies including checkpoint inhibit…

Dual Mode

Use your Hyperion XTi Imaging System to perform high-multiplex analysis of b…

Immuno-Oncology

Discover the impact of new immune therapies including checkpoint inhibit…

Case Studies

Lorem ipsum dolor sit amet consectetur

HER2 Trial, Clin. Cancer Res. 2019

Melanoma

IMC was used in a Phase 3 clinical trial of trastuzumab to stratify patients by HER2 expression levels, revealing how the dynamic range of HER2 expression and proximity to CD8+ T cells predicted patient response. Reference: Carvajal-Hausdorf, D.E. et al. 2019, Clinical Cancer Research.

HER2 Trial, Clin. Cancer Res. 2019

Breast Cancer

IMC was used in a Phase 3 clinical trial of trastuzumab to stratify patients by HER2 expression levels, revealing how the dynamic range of HER2 expression and proximity to CD8+ T cells predicted patient response. Reference: Carvajal-Hausdorf, D.E. et al. 2019, Clinical Cancer Research.

HER2 Trial, Clin. Cancer Res. 2019

Breast Cancer

Breast CancerIMC was used in a Phase 3 clinical trial of trastuzumab to stratify patients by HER2 expression levels, revealing how the dynamic range of HER2 expression and proximity to CD8+ T cells predicted patient response. Reference: Carvajal-Hausdorf, D.E. et al. 2019, Clinical Cancer Research.

Discover the throughput and precision that is uniquely designed for translational researchers.

Jana Fischer, PhD​​
Co-Founder and CEO, Navignostics​​

Discover the throughput and precision that is uniquely designed for translational researchers.

Jana Fischer, PhD​​
Co-Founder and CEO, Navignostics​​

Discover the throughput and precision that is uniquely designed for translational researchers.

Jana Fischer, PhD​​
Co-Founder and CEO, Navignostics​​
Workflow

Hyperion™ Imaging Systems use a one-step staining and detection approach that enables samples to be simultaneously stained, acquired and analyzed.

Biomarker Discovery

Identify therapeutic targets that may be relevant to developing treatment strat…

Simultaneous Detection of 40+ Markers

Identify therapeutic targets that may be relevant to developing treatment strat…

Hyperion™ Imaging Systems use a one-step staining and detection workflow that enables samples to be simultaneously stained, acquired and analyzed.

Lorem ipsum dolor sit amet consectetur

Biomarker Discovery

Identify therapeutic targets that may be relevant to developing treatment strat…

Biomarker Discovery

Identify therapeutic targets that may be relevant to developing treatment strat…

Explore

Resources and Data

Lorem ipsum dolor sit amet consec tetur adipisicing elit sed consec tetur adipisicing.

Flyers and brochures

Hyperion XTi Imaging System Brochure | FLDM-01130

Hyperion XTi Imaging System Brochure | FLDM-01130

Spotlight articles

Cancer Immunity, Autoimmunity and COVID-19 | Yongpan Yan, PhD

Download

Cancer Immunity, Autoimmunity and COVID-19 | Yongpan Yan, PhD

Download

Cancer Immunity, Autoimmunity and COVID-19 | Yongpan Yan, PhD

Download

Spotlight articles

Cancer Immunity, Autoimmunity and COVID-19 | Yongpan Yan, PhD

Download

Cancer Immunity, Autoimmunity and COVID-19 | Yongpan Yan, PhD

Download

Cancer Immunity, Autoimmunity and COVID-19 | Yongpan Yan, PhD

Download

Designed for high throughput and reproducibility, IMC offers the highest dynamic range in the industry, making it ideal for translational and clinical research. Whether focusing on oncology, immunology, or other complex diseases, these spatial proteomics solutions deliver the detailed insights needed to guide any phase of research.

Lorem ipsum dolor sit amet consectetur

Biomarker Discovery

Identify therapeutic targets that may be relevant to developing treatment strat…

Lorem ipsum dolor sit amet consectetur

Simultaneous Detection of 40+ Markers

Identify therapeutic targets that may be relevant to developing treatment strat…

Explore the Technology

Learn how our solutions uncover hidden proteomics
Scroll to Top